The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study

Table 5 Correlations¹ between PROs and clinical endpoints at baseline and week 12, and change from baseline to week 12

Measure	Baseline		Week 12		Change
	PASI	PGA	PASI	PGA	PASI	PGA
DLQI Total Score	0.31	0.29	0.67	0.65	0.69	0.71
SF-36
Physical Functioning	-0.32	-0.14 ns	-0.28	-0.25**	-0.38	-0.14 ns
Role-Physical	-0.22**	-0.14 ns	-0.41	-0.37	-0.42	-0.31
Bodily Pain	-0.36	-0.19*	-0.47	-0.42	-0.60	-0.44
General Health	-0.08 ns	0.05 ns	-0.34	-0.33	-0.34	-0.24**
Vitality	-0.15 ns	-0.06 ns	-0.37	-0.37	-0.38	-0.31
Social Functioning	-0.23**	-0.21**	-0.46	-0.38	-0.44	-0.43
Role-Emotional	-0.16 ns	-0.06 ns	-0.37	-0.29	-0.39	-0.36
Mental Health	-0.17*	-0.09 ns	-0.46	-0.38	-0.43	-0.36
Physical Summary	-0.28	-0.13 ns	-0.35	-0.33	-0.45	-0.25**
Mental Summary	-0.12 ns	-0.08 ns	-0.44	-0.36	-0.40	-0.42
EQ-5D
Index Score	-0.40	-0.31	-0.60	-0.51	-0.57	-0.44
VAS-General Health	-0.24**	-0.09 ns	-0.52	-0.43	-0.43	-0.38
PASI	1.00	0.59	1.00	0.83	1.00	0.75

¹All correlations were significant at p < 0.001, unless otherwise noted. *p ≤ 0.05, ** p < 0.01, ns = non-significant.

ISSN: 1477-7525